BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Affimed Therapeutics AG Appoints Chief Business Officer


6/5/2008 1:28:30 PM

Heidelberg, Germany – June 05, 2008 – Affimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, today announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer.

Dr. Lang joins Affimed from Scil Technology where he was Vice President of Corporate Development. At Scil Technology, he was responsible for the commercial development of a portfolio of regenerative medicine products including an eye-catching deal with Pfizer earlier this year. In his 16 years experience in the biotechnology sector, spanning basic research, industrial R&D, Business Development & Licensing, and commercial operations & management, Dr. Lang contributed significantly in the scientific development and commercialization of biological agents for industrial and healthcare applications.

“Dr. Lang’s has broad scientific knowledge and extensive experience in the sector of Business Development as well as his dynamic approach will be of great benefit to Affimed,” said Rolf H. Günther, MD PhD, Chief Executive Officer of Affimed. “This is particularly important as our product portfolio is now entering a very interesting phase with several milestones coming up”.

“Affimed has a strong track record in antibody research and a team assembled to translate that into commercial success,“ said Dr. Volker Lang, the new Chief Business Officer of Affimed. “I am excited and feel privileged to be joining the company at this pivotal stage.”

Dr. Lang replaces Gavin D Clark who has been working as VP Business Development for the last 2 years. Mr Clark is a founding partner at Procela Partners Limited and he will be continuing to consult for a number of early stage Biotech and Discovery Science based companies both in EU and US.

Dr. Lang combines a background as scientist and project manager with extensive experience in the commercialisation of biotechnology products. He has also gained considerable CMC/Production experience in his previous positions. Dr. Lang received his Ph.D. from the Technical University of Brunswick. After that he worked as an industry scientist and project manager with UCB-Celltech and Fresenius-Kabi, respectively. He joined Cosmix GmbH, Brunswick as Head of Business Development, and later Chief Operating Officer. Following Cosmix and prior to joining Scil Technology he was Vice President of Business Development at Pieris Proteolab AG.

About Affimed Therapeutics AG

Affimed is a private biopharmaceutical company based in Heidelberg, Germany specialising in the development of recombinant antibodies - the fastest growing segment of the pharmaceutical industry. Affimed was founded in May 2000 by Professor Melvyn Little as a spin-off of his group »Recombinant Antibodies« at the German Cancer Research Centre in Heidelberg. By utilizing its broad portfolio of proprietary, in-house technology platforms together with crucial enabling freedom-to-operate licenses, the company has been able to establish a pre-clinical product pipeline of promising novel product candidates mainly for indications in oncology and autoimmune diseases. To learn more about Affimed please visit www.affimed.com.

Further Information:

Dr Rolf Günther
Chief Executive Officer
Affimed Therapeutics AG
t: +49 (0)6221 65307 20
e: r.guenther@affimed.com

Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill Life Sciences
t : +49 (0)89 57 00 18 06
e: douglas.pretsell@collegehill.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES